Clinical trials: Epilepsy
Idiopathic Generalized Epilepsy, Partial Onset Seizures
A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
The primary purpose of this study is to assess the retention rate of perampanel as a reliable proxy for overall effectiveness and tolerability in participants aged at least 12 years who are prescribed perampanel (for partial…
- Conditions
- Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures
- Trial name
- NCT04252846
- Testing
- Perampanel
- Where
- 36 sites in Denmark, France and 5 more
- Volunteers
- 191 people
- Sponsor
- Eisai Limited
Seizures, Epilepsy
Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery
This study will asses the safety and efficacy of BGG492 in reducing the seizure rate in therapy-refractory partial seizures.
- Trial name
- NCT00887861
- Testing
- Investigational new drug, company code: BGG492
- Where
- 6 sites in Germany
- Volunteers
- 37 people
- Sponsor
- Novartis
Epilepsy, Tumor
Diffusion MRI-1 Imaging Database
The purpose of the dMRI-1 data collection study is to establish a database of clinical images and limited medical history information from patients that have previously received a dMRI scan.
- Conditions
- Epilepsy, Tumor, Healthy, Other
- Trial name
- dMRI-1 (NCT03775694)
- Testing
- dMRI Scan
- Where
- 6 sites in United States, Canada
- Volunteers
- 299 people, healthy volunteers welcome
- Sponsor
- Medtronic Spinal and Biologics
Partial Epilepsy
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
This purpose of this study is to measure the concentrations of two anti-epileptic drugs (Eslicarbazepine acetate and oxcarbazepine) and their metabolites in the cerebrospinal fluid and blood plasma of healthy subjects and also to…
- Trial name
- NCT00900237
- Testing
- Eslicarbazepine acetate, Oxcarbazepine
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsy
Comparison Of NeuroNaute Smart System to a Standard EleCTroencephalogram System in Hospital
The proposed study is designed to evaluate the performance of the Neuronaute in comparison with the gold standard EEG in patients with a regular appointment at the hospital.
- Trial name
- CONNECT (NCT03379272)
- Testing
- GOLDSTANDARD, NEURONAUTE
- Sponsor
- BioSerenity
Epilepsy
Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam
Phase IV, observational, post-authorization, cross sectional, open-label, multicenter study to evaluate the acceptability of oral solution of levetiracetam in patients with partial epilepsy as assessed by a questionnaire.
- Trial name
- NCT00319605
- Testing
- Levetiracetam
- Where
- 54 sites in Spain
- Volunteers
- 600 people
- Sponsor
- UCB Pharma
Birth Defects, Pregnancy Complications
UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)
This is a prospective, observational, exposure-registration and follow-up study of women and their offspring exposed to Keppra® (levetiracetam) and Keppra XR® at the time of conception (i.e., any time from the first day of the…
- Conditions
- Birth Defects, Pregnancy Complications, Epilepsy, Seizures
- Trial name
- NCT00345475
- Where
- United States
- Volunteers
- 516 people
- Sponsor
- UCB Pharma
Epilepsy
AED/Statin Interaction Study
This study will evaluate the amount of the cholesterol-lowering drug atorvastatin available in the bloodstream, when taken together with the anti-seizure drugs lamotrigine or phenytoin.
- Trial name
- NCT00627575
- Testing
- lamotrigine, atorvastatin, phenytoin
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Epilepsy
IMPACT of AspireSR® for VNS Therapy on Healthcare Resource Utilisation and Clinical Outcomes.
This is a retrospective non-interventional study to describe the HCRU and clinical outcomes before and after AspireSR® device implantation in subjects with drug resistant epilepsy at the Queen Elizabeth Hospital, Birmingham…
- Trial name
- IMPACT (NCT05975931)
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- LivaNova
Epilepsy With Partial On-set Seizures
A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures
- Trial name
- NCT03116828
- Testing
- Eslicarbazepine acetate
- Where
- 55 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Sumitomo Pharma America, Inc.
Epilepsy
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
The main purpose of this study is to evaluate the effectiveness of the study drug lacosamide (200-600 mg/day) when added to a stable dose of levetiracetam (1000-3000 mg/day) with withdrawal of the concomitant sodium channel…
- Trial name
- VERVE (NCT01484977)
- Testing
- Lacosamide
- Where
- 54 sites in United States, Australia and 7 more
- Volunteers
- 120 people
- Sponsor
- UCB Pharma
Epilepsy
A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy
The purpose of the study is to assess the pharmacokinetics (PK), tolerability, and safety of Staccato alprazolam in adolescent study participants with epilepsy following single-dose administration.
- Trial name
- NCT04857307
- Testing
- Alprazolam
- Where
- 8 sites in United States
- Volunteers
- 14 people
- Sponsor
- UCB Biopharma SRL
Epilepsy
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
The purpose of this study is to evaluate the safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures, who completed the…
- Trial name
- NCT00310375
- Testing
- Ezogabine: USAN Retigabine (International Nonproprietary Name)
- Where
- 51 sites in United States, Argentina and 3 more
- Volunteers
- 181 people
- Sponsor
- GlaxoSmithKline
Epilepsy, Tonic-Clonic
Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug
The purpose of this study is to evaluate the effectiveness and safety of an investigational new drug for supplemental therapy in subjects with primary generalized tonic-clonic (PGTC) seizures.
- Trial name
- NCT00043901
- Testing
- lamotrigine
- Where
- 87 sites in United States, Argentina and 2 more
- Volunteers
- 141 people
- Sponsor
- GlaxoSmithKline
Epilepsy, Lennox Gastaut Syndrome
Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
The primary objective of this study was to evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo in participants with Lennox-Gastaut syndrome (LGS).
- Trial name
- GWPCARE3 (NCT02224560)
- Testing
- GWP42003-P
- Where
- 29 sites in United States, France and 2 more
- Volunteers
- 225 people
- Sponsor
- Jazz Pharmaceuticals
Drug Resistant Epilepsy, Autism Spectrum Disorder
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
The goal of this observational study is to learn about the clinical and nutritional effectiveness of ketogenic diet (KD) in pediatric patients with genetic, neurological or metabolic conditions requiring KD.
- Conditions
- Drug Resistant Epilepsy, Autism Spectrum Disorder, Chronic Migraine, Brain Tumor, Pediatric
- Trial name
- NCT06309251
- Testing
- ketogenic diet (as per clinical practice)
- Where
- 3 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Danone Nutricia SpA Società Benefit
Epilepsy, Partial
Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
Community based study assessing safety and efficacy of levetiracetam in partial onset seizures. The optimal dose in daily clinical practice will be used.
- Trial name
- NCT00160654
- Testing
- Levetiracetam
- Where
- 29 sites in Hong Kong, Malaysia and 4 more
- Volunteers
- 251 people
- Sponsor
- UCB Pharma
Focal Epilepsy
ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures
The ENACT trial is designed to evaluate the efficacy and safety of ENX-101 administered adjunctively to current therapy in reducing seizure frequency in patients diagnosed with focal (partial onset) epilepsy and treated with 1 to…
- Trial name
- ENACT (NCT05481905)
- Testing
- ENX-101
- Where
- 38 sites in United States
- Sponsor
- Engrail Therapeutics INC
Unverricht-Lundborg Disease
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults
The study will compare the efficacy and safety of brivaracetam with placebo in patients with Unverricht-Lundborg disease.
- Trial name
- NCT00357669
- Testing
- Brivaracetam 25 mg, Brivaracetam 50 mg
- Where
- 13 sites in Finland, France and 5 more
- Volunteers
- 50 people
- Sponsor
- UCB Pharma SA
Unverricht-Lundborg Disease
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults
The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD).
- Trial name
- NCT00368251
- Testing
- BRV 2.5 mg, BRV 25 mg, BRV 50 mg
- Where
- 18 sites in United States, Canada and 6 more
- Volunteers
- 56 people
- Sponsor
- UCB Pharma